Exscientia Takes Single Molecules To Multiple Pathways In Diabetes
Seeking Alpha Innovation in diabetes seems to have reached a plateau, with recently launched drugs focusing on combinations and quick- or extended-action formulations. Sanofi's (NYSE:SNY) recent collaboration with private UK group Exscientia is taking drug discovery ... |
Social Plugin